DetermaIO algorithm and qPCR assay are used to show an association with molecular features of gastric cancer that have also been previously shown to be associated with response to ICI therapies so this is important because gastric cancer is the fifth most incident cancer worldwide and the third leading cause of cancer-related death worldwide and so unfortunately most gastric cancers are asymptomatic and go undiagnosed until they are in late stage and so as a result the survival outcomes for late-stage gastric cancers are exceedingly poor and so we need better treatments and detection mechanisms for identifying patients who are likely to respond to therapy in these late stages as time is critical so currently the most of the first line treatments involve chemotherapy or surgery and immunotherapies or immune checkpoint inhibitor therapy has been approved in the US for second and third line therapies but recently ICI therapy has also been now included for first line therapy and gastric cancer so currently there's a variety of biomarkers out there that are used for a prognostic determination of a response to ICI therapy and these include things like PD⁠-⁠L1 one score at a threshold of one percent t or mutational burden EVV status and MSI high tumors so as I mentioned currently ICIs are currently improving the US for advanced gastric cancer in the second line or third line setting but different trials have demonstrated a wide range of response rates in advanced and metastatic gastric cancer in the salvage therapy setting or second and third line setting and with or without PD⁠-⁠L11 positivity and so this opens the door for the opportunity to look for better biomarkers that could be used to predict response to therapy.

So, one of the biomarkers that is of potential use is the DetermaIO biomarker which is what we call the IO score here and the term io is a 27 gene assay that can be used either by real-time qPCR or RNA-seq and it's used to identify the tumor immune micro environment and identifies patients as a binary result immunoscope positive or negative or pardon IO score positive or negative and those that are IO score positive are likely more likely to respond to immune checkpoint inhibitor therapy compared to those who are IO negative so this assay really seeks to classify the tumor immune microenvironment in a tumor agnostic fashion and we've had previous data show that the io score is predictive of response and triple negative breast cancer and is also associated with response in non-small cell lung cancers so in this study this is more of a proof-of-principle small study in which we took data RNA-seq data from either the TCGA database or the Asian cancer research group ACRG database and looked at the association between the IO score and the other molecular features and so what we saw was that indeed the io score was significantly associated with the known...To Read The Rest of the Transcript or Watch the Video Click Here